Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 14;13(3):213.
doi: 10.3390/toxins13030213.

Botulinum Toxin A and Osteosarcopenia in Experimental Animals: A Scoping Review

Affiliations

Botulinum Toxin A and Osteosarcopenia in Experimental Animals: A Scoping Review

Min Jia Tang et al. Toxins (Basel). .

Abstract

We conducted a scoping review to investigate the effects of intramuscular injection of Botulinum Toxin A (BoNT-A) on bone morphology. We investigated if the muscle atrophy associated with Injection of BoNT-A had effects on the neighboring bone. We used the search terms: osteopenia, bone atrophy, Botulinum Toxin A, Micro-CT, mice or rat. The following databases were searched: Medline, Embase, PubMed and the Cochrane Library, between 1990 and 2020. After removal of duplicates, 228 abstracts were identified of which 49 studies satisfied our inclusion and exclusion criteria. The majority of studies (41/49) reported a quantitative reduction in at least one measure of bone architecture based on Micro-CT. The reduction in the ratio of bone volume to tissue volume varied from 11% to 81% (mean 43%) according to the experimental set up and study time points. While longer term studies showed muscle recovery, no study showed complete recovery of all bone properties at the termination of the study. In experimental animals, intramuscular injection of BoNT-A resulted in acute muscle atrophy and acute degradation of the neighboring bone segment. These findings may have implications for clinical protocols in the use of Botulinum Toxin in children with cerebral palsy, with restraint recommended in injection protocols and consideration for monitoring bone density. Clinical studies in children with cerebral palsy receiving injections of Botulinum are indicated.

Keywords: Botulinum Toxin A; cerebral palsy; experimental animals; muscle atrophy; osteopenia; sarcopenia.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA Scoping Review Study Diagram.

Similar articles

Cited by

References

    1. Graham H.K., Rosenbaum P., Paneth N., Dan B., Lin J.-P., Damiano D.L., Becher J.G., Gaebler-Spira D., Colver A., Reddihough D.S., et al. Cerebral palsy. Nat. Rev. Dis. Primers. 2016;2:15082. doi: 10.1038/nrdp.2015.82. - DOI - PMC - PubMed
    1. Multani I., Manji J., Hastings-Ison T., Khot A., Graham K. Botulinum Toxin in the Management of Children with Cerebral Palsy. Paediatr. Drugs. 2019;21:261–281. doi: 10.1007/s40272-019-00344-8. - DOI - PMC - PubMed
    1. Bhidayasiri R., Truong D.D. Expanding use of botulinum toxin. J. Neurol. Sci. 2005;235:1–9. doi: 10.1016/j.jns.2005.04.017. - DOI - PubMed
    1. Tarabal O., Calderó J., Ribera J., Sorribas A., López R., Molgó J., Esquerda J.E. Regulation of Motoneuronal Calcitonin Gene-related Peptide (CGRP) During Axonal Growth and Neuromuscular Synaptic Plasticity Induced by Botulinum Toxin in Rats. Eur. J. Neurosci. 1996;8:829–836. doi: 10.1111/j.1460-9568.1996.tb01269.x. - DOI - PubMed
    1. Multani I., Manji J., Tang M.J., Herzog W., Howard J.J., Graham H.K. Sarcopenia, Cerebral Palsy, and Botulinum Toxin Type A. JBJS Rev. 2019;7:e4. doi: 10.2106/JBJS.RVW.18.00153. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources